Contrasting INVO Fertility (NASDAQ:IVF) & Biostage (OTCMKTS:BSTG)

Biostage (OTCMKTS:BSTG) and INVO Fertility (NASDAQ:IVF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings for Biostage and INVO Fertility, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostage	0	0	1	0	3.00
INVO Fertility	1	0	0	1	2.50

INVO Fertility has a consensus price target of $20.00, suggesting a potential upside of 834.58%. Given INVO Fertility’s higher possible upside, analysts plainly believe INVO Fertility is more favorable than Biostage.

Profitability

This table compares Biostage and INVO Fertility’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostage	N/A	N/A	-174.43%
INVO Fertility	-417.02%	N/A	-92.42%

Insider & Institutional Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 15.3% of Biostage shares are owned by insiders. Comparatively, 0.7% of INVO Fertility shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Biostage and INVO Fertility”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostage	N/A	N/A	-$6.07 million	($0.58)	-7.67
INVO Fertility	$6.53 million	0.53	-$9.10 million	($3,151.46)	0.00

Biostage has higher earnings, but lower revenue than INVO Fertility. Biostage is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biostage has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500. Comparatively, INVO Fertility has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500.

Summary

INVO Fertility beats Biostage on 7 of the 13 factors compared between the two stocks.

About Biostage

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.